Orla Protein Technologies awarded Innovate UK project to develop tools for use during checkpoint inhibitor drug development
Orla Protein Technologies is proud to announce to have been chosen as a recipient of an Innovate UK grant for the development of proteins for use in the development of anti-cancer biopharmaceuticals. The project starting in April 2017 aims to engineer and develop five proteins for surface-application that will support development of drugs targeting immune checkpoint pathways.
Orla’s proprietary technology OrlaSURF enables the engineering and immobilisation of proteins on surfaces. Our engineered proteins are being used across the biopharmaceutical development process and for manufacturing. Its newest application involves the immobilisation of proteins for use during development and optimisation of immuno-oncology biopharmaceuticals.
Immuno-oncology therapy has huge potential for treatment of cancer patients as it enables the body’s own immune system to help fight cancer. Proteins expressed on cancer cells have the ability to bind to proteins expressed on the surface of T-cells preventing the immune system targeting the cancer cells. Checkpoint inhibitor drugs aim to block the interaction of T-cell proteins and cancer cell proteins in order to activate the body’s own immune-response to the cancerous cells. Drug developers need tools to test and optimise these drugs to ensure highest possible effectiveness.
In this Innovate UK co-funded project we are developing tools for use during development of biopharmaceuticals that target immune checkpoint pathways. We will develop a range of PD-1, PD-L1, CD80, CTLA-4, and LAG3 fusion proteins based on our proprietary protein engineering platform. These molecules can then be used for testing the binding and inhibitory function of mAbs targeting checkpoint pathways across analytical instruments including ELISA, Octet, and Biacore.
“Our molecules will help scientists to analyse the effectiveness of anti-cancer drugs and ultimately to accelerate their development and manufacture.” – Dr Sion Phillips, Technical Project Leader of the project, explains.
About Orla Protein Technologies
Orla Protein Technologies is specialised in the design, engineering and manufacture of recombinant proteins, particularly for surface applications. Our patented OrlaSURF technology enables the creation of highly oriented and functional protein surfaces and is used commercially in a diverse range of Life Science applications such as bioanalytical devices, cell culture, bioseparations, and assay development.